{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Subcutaneous+immune+globulin+G", "query": { "intervention": "Subcutaneous immune globulin G" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 65, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Subcutaneous+immune+globulin+G&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-28T18:55:12.719Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04656418", "title": "CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hereditary Angioedema" ], "interventions": [ { "name": "CSL312", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "CSL Behring", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 64, "start_date": "2021-01-27", "completion_date": "2022-06-07", "has_results": true, "last_update_posted_date": "2023-06-29", "last_synced_at": "2026-09-28T18:55:12.719Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Santa Monica, California + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Chevy Chase", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04656418" }, { "nct_id": "NCT00482053", "title": "Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, B-cell", "Lymphoma, Non-Hodgkin", "Diffuse Large B-cell Lymphoma (DLBCL)", "Malignant Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Autologous hematopoietic stem cell transplantation (auto-HSCT)", "type": "PROCEDURE" }, { "name": "Allogeneic hematopoietic stem cell transplantation (allo-HSCT)", "type": "PROCEDURE" }, { "name": "Total lymphoid irradiation (TLI)", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Anti-thymocyte globulin (ATG)", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 3, "start_date": "2006-10", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2018-05-14", "last_synced_at": "2026-09-28T18:55:12.719Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00482053" }, { "nct_id": "NCT02613910", "title": "Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pemphigus" ], "interventions": [ { "name": "Ofatumumab", "type": "DRUG" }, { "name": "Acetaminophen/paracetamol", "type": "DRUG" }, { "name": "Antihistamine (cetirizine or equivalent)", "type": "DRUG" }, { "name": "Prednisone/Prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1, "start_date": "2015-12-23", "completion_date": "2016-03-23", "has_results": true, "last_update_posted_date": "2017-06-14", "last_synced_at": "2026-09-28T18:55:12.719Z", "location_count": 2, "location_summary": "Los Angeles, California • Ann Arbor, Michigan", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02613910" }, { "nct_id": "NCT05755035", "title": "A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Primary Immunodeficiency Diseases (PID)" ], "interventions": [ { "name": "TAK-881", "type": "BIOLOGICAL" }, { "name": "HYQVIA", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 65, "start_date": "2023-10-24", "completion_date": "2026-01-20", "has_results": false, "last_update_posted_date": "2026-02-03", "last_synced_at": "2026-09-28T18:55:12.719Z", "location_count": 15, "location_summary": "Irvine, California • Walnut Creek, California • Denver, Colorado + 12 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Macon", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05755035" }, { "nct_id": "NCT04558736", "title": "Haploidentical HCT for Severe Aplastic Anemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Aplastic Anemia", "Bone Marrow Failure Syndrome" ], "interventions": [ { "name": "Anti-Thymocyte Globulin (Rabbit)", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Total Lymphoid Irradiation (TLI)", "type": "RADIATION" }, { "name": "CliniMACS", "type": "DEVICE" }, { "name": "HPC, A Infusion", "type": "BIOLOGICAL" }, { "name": "CD45RA-depleted DLI", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "RADIATION", "DEVICE", "BIOLOGICAL" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 21, "start_date": "2021-01-21", "completion_date": "2030-07-01", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-09-28T18:55:12.719Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04558736" }, { "nct_id": "NCT00450801", "title": "R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Thalidomide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Filgrastim (G-CSF)", "type": "DRUG" }, { "name": "Granisetron", "type": "DRUG" }, { "name": "Decadron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2004-04", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2015-11-10", "last_synced_at": "2026-09-28T18:55:12.719Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00450801" }, { "nct_id": "NCT00389324", "title": "A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Immunologic Deficiency Syndrome" ], "interventions": [ { "name": "Immune Globulin Intravenous (Human)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "13 Years to 75 Years" }, "enrollment_count": 35, "start_date": "2006-11", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2015-04-20", "last_synced_at": "2026-09-28T18:55:12.719Z", "location_count": 6, "location_summary": "Irvine, California • Los Angeles, California • Atlanta, Georgia + 3 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00389324" }, { "nct_id": "NCT02123615", "title": "ASIS for GAMMAGARD in Primary Immunodeficiency", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Primary Immunodeficiency" ], "interventions": [ { "name": "Gadolinium For abdomen", "type": "DRUG" }, { "name": "Gadolinium For lower back", "type": "DRUG" }, { "name": "Efficacy of Gammagard subcutaneously at Week 12", "type": "DRUG" }, { "name": "Efficacy of Gammagard subcutaneously at Week 24", "type": "DRUG" }, { "name": "Efficacy of Gammagard subcutaneously at Week 36", "type": "DRUG" }, { "name": "Efficacy of Gammagard subdermally at Week 36", "type": "DRUG" }, { "name": "Efficacy of Gammagard subdermally at Week 12", "type": "DRUG" }, { "name": "Efficacy of Gammagard subdermally at Week 24", "type": "DRUG" }, { "name": "Adverse Reactions of Gammagard subcutaneously at Week 12", "type": "DRUG" }, { "name": "Adverse Reactions of Gammagard subcutaneously at Week 24", "type": "DRUG" }, { "name": "Adverse Reactions of Gammagard subcutaneously at Week 36", "type": "DRUG" }, { "name": "Adverse Reactions of Gammagard subdermally at Week 12", "type": "DRUG" }, { "name": "Adverse Reactions of Gammagard subdermally at Week 24", "type": "DRUG" }, { "name": "Adverse Reactions of Gammagard subdermally at Week 36", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ASIS Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2016-01", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2015-06-24", "last_synced_at": "2026-09-28T18:55:12.719Z", "location_count": 1, "location_summary": "Westminster, California", "locations": [ { "city": "Westminster", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02123615" }, { "nct_id": "NCT05684692", "title": "Screening Trial for Pain Relief in Schwannomatosis (STARFISH)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schwannomatosis", "Schwannomas", "Pain, Chronic" ], "interventions": [ { "name": "Siltuximab", "type": "DRUG" }, { "name": "Erenumab-Aooe", "type": "DRUG" }, { "name": "Siltuximab Matching Placebo", "type": "DRUG" }, { "name": "Erenumab-Aooe Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2023-08-31", "completion_date": "2028-11-30", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-09-28T18:55:12.719Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05684692" }, { "nct_id": "NCT00671658", "title": "Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide (CTX)", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Methotrexate (MTX)", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Pegylated asparaginase", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Solumedrol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 220, "start_date": "2002-11", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2020-12-03", "last_synced_at": "2026-09-28T18:55:12.719Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00671658" } ] }